Retinal Vein Occlusion
VIDEO: Faricimab for retinal vein occlusion helpful in real-world practice
In this expert perspective, Manjot K. Gill, MD, discusses faricimab for the management of retinal vein occlusion.
VIDEO: Aflibercept 8 mg may offer enhanced efficacy, durability in retinal vein occlusion
In this expert perspective, Manjot K. Gill, MD, discusses the potential FDA approval in 2025 of aflibercept 8 mg for the treatment of retinal vein occlusion.
VIDEO: Vabysmo prefilled syringe offers potent, durable treatment option for RVO
In this expert perspective from Hawaiian Eye 2025, Ashkan M. Abbey, MD, discusses an advancement in retinal vein occlusion treatment from 2024 and highlights a treatment in the pipeline for 2025.
VIDEO: Data support use of aflibercept 8 mg in treatment of retinal vein occlusion
In this expert perspective from Hawaiian Eye 2025, W. Lloyd Clark, MD, discusses the use of aflibercept 8 mg in the treatment of retinal vein occlusion.
VIDEO: RVO often overlooked in retinal space
In this expert perspective from Hawaiian Eye 2025, Roger A. Goldberg, MD, MBA, highlights advancements in the treatment of retinal vein occlusion.
VIDEO: Multimodal imaging essential for geographic atrophy management
KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Roger A. Goldberg, MD, MBA, discusses the role of multimodal imaging in geographic atrophy in the era of complement inhibitors.
Clinical Trial Updates in nAMD, DME, RVO, MacTel, and GA Management
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; Neurotech Pharmaceuticals, Inc.; Astellas; EyePoint Pharmaceuticals, Inc.; Opthea Ltd.; Topcon Healthcare, Inc.; Outlook Therapeutics; REGENXBIO Inc.; Ocuphire Pharma; and Carl Zeiss Meditec, Inc.
FDA news: Top items in ophthalmology for 2024
Healio’s top FDA articles in ophthalmology this year included updates on the Vabsymo prefilled syringe, two new aflibercept biosimilars and an oral therapy for Stargardt disease.
Eylea HD meets primary endpoint of improved vision in phase 3 retinal vein occlusion trial
Eylea HD improved vision with extended dosing intervals in patients with macular edema following retinal vein occlusion in the phase 3 QUASAR trial, according to a press release from Regeneron.
European committee issues positive opinion for Eylea biosimilar
The Committee for Medicinal Products for Human Use of the European Medicines Agency granted a positive opinion for Eydenzelt, a biosimilar to Eylea, according to a press release from Celltrion.